Mill Valley, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Glomerular Disease Study and Trial Consortium, founded in 2021, is a small nonprofit in the Medical Research sector that reported $935K in total revenue in fiscal year 2023. Revenue surged 192% from the prior year, signaling strong growth momentum. The organization ran a surplus of $704K, a strong 75% operating margin.
The primary purposes of the corporation shall be to raise awareness about, promote diagnosis and treatment of, and help patients with kidney diseases, by: (1) creating and providing scientific, clinical, and educational materials, seminars, training, and other forms of medical education to medical professionals and the public; (2) conducting and providing infrastructure and other forms of support for patient registries, biomarker studies, and genomic research; and (3) collaborating with other charitable organizations exempt under Section 501(c)(3) of the Code focused on rare kidney diseases in furtherance of the foregoing purposes.
6000 GlomCon participants in 2023GlomCon Educational
GlomCon Research
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $935,437 | $320,412 | +1.9% |
| Expenses | $230,972 | $92,317 | +1.5% |
| Net Income | $704,465 | $228,095 | +2.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Dr Maria Ansari | Board Member | 0.25 |
Director
|
$0 | $0 | $0 |
| Dr Martin Pollak | Board Member | 0.25 |
Director
|
$0 | $0 | $0 |
| Dr Ali Poyan Mehr | President | 10.00 |
Officer
|
$0 | $0 | $0 |
| Dr Tingting Li | Secretary | 0.25 |
Officer
|
$0 | $0 | $0 |
| Olga Yurchenko | CFO/Treasurer | 0.50 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $935,437 | $230,972 | $968,603 | $704,465 |
| 2022 | $320,412 | $92,317 | $264,096 | $228,095 |
Compare Glomerular Disease Study and Trial Consortium with other nonprofits in California and across the country.